Search

To achieve a fully automatic artificial pancreas (AP), i.e., an AP without the need for meal announcements, the intraperitoneal (IP) route is explored. This route has faster dynamics than the typical subcutaneous (SC) route. Model predictive control (MPC) is the most promising control algorithm, but it requires a predictive and identifiable model. This paper presents the design of such a model for MPC-based dual hormone IP APs. This model is trained and tested on recorded data from anesthetized pigs. Animal experiments show that the saturation of the hepatic first-pass effect is essential in how IP insulin and IP glucagon affect glucose levels. These physiological phenomena must be modeled to estimate the system behavior for various conditions. This, in turn, increases the number of parameters and complicates system identification. The availability of rich experimental data from 26 animal trials motivated the design of a technique to exploit this prior information to ensure the identifiability of our model. Through this technique, most parameters were either modeled as body weight functions or common among animals. The correlation between parameter values and body weight is discovered utilizing prior data from various animal experiments, such as blood glucose, plasma insulin, and glucagon levels, in which hormones were administered intraperitoneally or intravenously. This method simplifies the system identification for every new subject while keeping the model’s essential details that improve the prediction capability relative to comparable models. The model can be exploited in MPC or any other model-based controller of a bi-hormonal IP AP. It can also be used as a simulator to develop control approaches for single and bi-hormonal IP APs.

Aims: To conduct a pooled analysis to assess the performance of intermittently scanned continuous glucose monitoring (isCGM) in association with the rate of change in sensor glucose in a cohort of children, adolescents, and adults with type 1 diabetes. Material and methods: In this pooled analysis, isCGM system accuracy was assessed depending on the rate of change in sensor glucose. Clinical studies that have been investigating isCGM accuracy against blood glucose, accompanied with collection time points were included in this analysis. isCGM performance was assessed by means of median absolute relative difference (MedARD), Parkes error grid (PEG) and Bland-Altman plot analyses. Results: Twelve studies comprising 311 participants were included, with a total of 15 837 paired measurements. The overall MedARD (interquartile range) was 12.7% (5.9-23.5) and MedARD differed significantly based on the rate of change in glucose (P < 0.001). An absolute difference of -22 mg/dL (-1.2 mmol/L) (95% limits of agreement [LoA] 60 mg/dL (3.3 mmol/L), -103 mg/dL (-5.7 mmol/L)) was found when glucose was rapidly increasing (isCGM glucose minus reference blood glucose), while a -32 mg/dL (1.8 mmol/L) (95% LoA 116 mg/dL (6.4 mmol/L), -51 mg/dL (-2.8 mmol/L)) absolute difference was observed in periods of rapidly decreasing glucose. Conclusions: The performance of isCGM was good when compared to reference blood glucose measurements. The rate of change in glucose for both increasing and decreasing glucose levels diminished isCGM performance, showing lower accuracy during high rates of glucose change. Keywords: continuous glucose monitoring (CGM); type 1 diabetes.

The continuous glucose monitoring (CGM) system is the most common system used by people with type 1 diabetes to monitor blood glucose levels. However, it measures glucose in interstitial fluid in subcutaneous tissue rather than directly in plasma. Measuring blood glucose level in this method has slow dynamics and introduce a time lag in capturing the blood glucose level. This can reduce the quality of blood glucose regulation and result in hypo- or hyperglycemia. In this paper, a linear Kalman filter is developed to predict blood glucose concentration using CGM data to compensate for that slow dynamics. To this end, an observable input-less model describing the glucose diffusion from plasma to interstitial fluid is utilized. Notably, this model is physiology-based, and its parameters can be obtained from the literature. The designed structure is evaluated on data from two animal experiments conducted on anesthetized pigs. The data sets include CGM measurements every 1.2 seconds and sporadic blood sample analysis during experiments. Results show that the designed approach sufficiently can compensate for the slow dynamics of CGM measurements when compared to blood glucose samples, and the performance is measured using statistical accuracy scores. This compensation can improve the decision-making of control algorithms for glucose regulation during rapid changes in glucose concentration, e.g., during meals and exercise.

Currently, continuous glucose monitoring sensors are used in the artificial pancreas to monitor blood glucose levels. However, insulin and glucagon concentrations in different parts of the body cannot be measured in real-time, and determining body glucagon sensitivity is not feasible. Estimating these states provides more information about the current system status, facilitating improved decision-making by the model-based controller. In this regard, the aim of this paper is to design a nonlinear high-gain observer for a bi-hormonal artificial pancreas in the presence of measurement noises, model uncertainties, and disturbances. The model used in the observer is based on an existing intraperitoneal nonlinear animal model in the literature. This model is modified by assuming that insulin can directly transfer from the peritoneal cavity to the bloodstream. Based on a set of realistic assumptions, one model is considered after each hormone infusion, and two observers are separately designed. The model is divided into the insulin-phase and glucagon-phase models based on a set of realistic assumptions. Thereafter, two high-gain observers are designed separately for these phases contributing to estimating the non-measurable states. The observer error is proven to be locally uniformly ultimately bounded, and it is verified that any asymptotically stable control laws remain stable in the presence of the observer. The performance of the observers with different gains is evaluated for a scenario with multiple insulin and glucagon infusions. The proposed observer converges to a finite error, according to the results. Clinical relevance- In Type 1 diabetic patients, the developed observer can be employed in a closed-loop artificial pan-creas to improve the performance of model-based controllers. It estimates the key states, which are necessary for forecasting the body's response to insulin and glucagon boluses.